Levetiracetam Accord Healthcare (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, decreasing neuronal hyper‑excitability and stabilising abnormal electrical activity in the brain, thereby providing an anticonvulsant effect.

The specific dose of Levetiracetam Accord Healthcare is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type and response to therapy. No fixed regimen is provided here.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam has a unique mechanism involving SV2A binding, which differs from many older antiepileptics that target ion channels or G‑protein pathways. It is generally well tolerated, has minimal drug‑enzyme interactions, and is often used when other agents are ineffective or cause intolerable side effects.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Levetiracetam Accord Healthcare is taken orally, usually as a tablet. It can be swallowed whole with water and may be taken with or without food, as directed by the prescribing clinician.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, significant mood changes including depression or suicidal thoughts, and rare hematologic abnormalities like neutropenia. Patients should be monitored closely for these events.

Patients with known hypersensitivity to levetiracetam or any of its excipients should avoid the product. Caution is advised in individuals with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications listed under major interactions.